» Download Public Reports
About 300 reports
- Company report
- May 2013
- 16 pages
... And transportation, and while undergoing handling, manipulation and processing by researchers engaged in regenerative medicine product development. Demand for biopreservation media is estimated to grow at an annual ...
May 2013
... This year Eu regulatory filing submitted April 2013 Tremor study differentiation results May 2013 Phase iii pivotal study results in de novo kidney transplant Mid-2013 Us regulatory filing ...
April 2013
... Increased focus on blood conservation strategies Development of provincial blood coordinating offices Changing paradigm of transfusion as a medical therapy focus on blood conservation Largest program ...
April 2013
... Q4 12 q1 12 q2 12 q3 12 q4 475,000 500,000 525,000 550,000 575,000 600,000 american red cross blood centers of america source: blood centers of america and arcinternal data accounting for >60% of us ...
April 2013
... Of transfusions while ensuring each patient is looked at as an individual definitions of patient blood management percentage of hospital blood bankdirectors/managers conservative transfusion approach 20% evaluating ...
March 2013
... Not requiring cold storage (e.G. Modified, plasma, platelets, & red blood cells and oxygen carrying solutions) % rapid low technology screening tests for infectious diseases % pathogen reduced blood ...
March 2013
... Process. These processes are activated at the blood banks. Almost 90% of the blood supply in the united states, as well as 80% of transfusions, is co-ordinated through these blood banks, and other publicly ...
March 2013
... Results indicate that simulation can be used to represent blood supply chain operation in the maritime region. Both the physical test and the simulation models show that product availability ...
February 2013
... Of these adverse reactions from blood transfusions is 1 in 394 transfusions, a number believed to be even higher because of underreporting, according to the most recent data from the national blood collection ...
February 2013
... Injury in dcd grafts Modify allocation rules to increase access to retransplantation after failed dcd liver transplants Refine understanding of risk factors of dcd liver transplants http ...
» Purchase Premium Reports
(From $ 125 - $ 1 020)
92 reports
- $ 1 020
- Industry report
- April 2013
- by Ibisworld
IBISWORLD INDUSTRY RISK RATINGS REPORT This is the replacement for IBISWorld's November Blood & Organ Banks in the US Industry Risk Ratings Report. Industry Risk Ratings Synopsis This Industry Risk Ratings ...
April 2013
$ 750
Summary W. L. Gore & Associates, Inc. (Gore) carries out the manufacture and marketing of fluoro-polymer products for the medical, electronics, nuclear, fabrics and industrial markets. The company's medical ...
May 2013
$ 750
Summary TEI Biosciences, Inc. (TEI) is a biomedical company. The company develops and commercializes novel biological products for soft tissue repair, reconstruction and reinforcement applications. Its ...
May 2013
$ 250
Summary Quark Pharmaceuticals, Inc. (Quark) is a pharmaceutical company. The company discovers and develops novel therapeutic RNAi drug candidates. Its products pipeline include PF-655 (RTP801i14), QPI ...
May 2013
$ 250
Summary Cerus Corporation (Cerus) is a biomedical products manufacturing company which undertakes the development and commercialization of novel, proprietary products and technologies, intended to make ...
May 2013
$ 250
This report is systematically updated by our analysts for each new purchase. This is to ensure that you get the latest information available on the company. The report will be updated and sent to you in ...
May 2013
$ 250
Summary Terumo BCT, Inc. (Terumo BCT) formerly CaridianBCT, Inc., is a medical device company. It develops products related to the fields of blood banking, therapeutic apheresis and transfusion medicine ...
